Anavex Life Sciences Corp (AVXL)

[anders2211]

Going after RETT is a good decision if the were not already so many other biotechs persuing the disease. I agree with you that it is enormous for Fragile X and ASD which would have been better to pursue. Since there are now reliable indications that Alzheimer's is doing really well Missling decision probably is the best he ever made.. but a risky one true.

But in general, I agree with you exclusive rare disease would have bene better.

By the way

As you probably know, novel drugs for rare diseases like Rett can command upwards of $200,000 a year.

One cannot charge 200k per patient for RETT and then less or more for a not rare disease...